BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 28278446)

  • 21. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.
    Buchegger F; Garibotto V; Zilli T; Allainmat L; Jorcano S; Vees H; Rager O; Steiner C; Zaidi H; Seimbille Y; Ratib O; Miralbell R
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):68-78. PubMed ID: 24104592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-phase (18)F-fluorocholine PET/CT to detect locoregional recurrence of prostate cancer: comparison between each time point of imaging and a summation scan.
    Tong AK; Zhang ZX; Zaheer S; Yan XS
    Clin Imaging; 2016; 40(3):486-91. PubMed ID: 27133692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
    Chakraborty D; Bhattacharya A; Mete UK; Mittal BR
    Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy.
    Picchio M; Spinapolice EG; Fallanca F; Crivellaro C; Giovacchini G; Gianolli L; Messa C
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):13-26. PubMed ID: 21932120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
    Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer.
    Evangelista L; Cimitan M; Hodolič M; Baseric T; Fettich J; Borsatti E
    Abdom Imaging; 2015 Oct; 40(8):3230-7. PubMed ID: 26428685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early ¹⁸F-FCH PET/CT?
    Di Biagio D; Chiaravalloti A; Tavolozza M; Abbatiello P; Schillaci O
    Ann Nucl Med; 2015 Dec; 29(10):861-9. PubMed ID: 26261000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    von Eyben FE; Kairemo K
    Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of 18F-fluorocoline PET/CT in prostate cancer patients with biochemical recurrence: Influence of PSA kinetics and hormone therapy.
    Triviño-Ibáñez EM; Puche-Sanz I; Gómez-Río M; Cózar Olmo JM; Llamas-Elvira JM; Rodríguez-Fernández A
    Med Clin (Barc); 2019 Jul; 153(2):56-62. PubMed ID: 30660434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
    Witkowska-Patena E; Giżewska A; Dziuk M; Miśko J; Budzyńska A; Walęcka-Mazur A
    Clin Nucl Med; 2019 Dec; 44(12):e629-e633. PubMed ID: 31689286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)/computed tomography (CT) and [(18) F]NaF PET/CT.
    Poulsen MH; Petersen H; Høilund-Carlsen PF; Jakobsen JS; Gerke O; Karstoft J; Steffansen SI; Walter S
    BJU Int; 2014 Dec; 114(6):818-23. PubMed ID: 24314065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significant increase in detection of prostate cancer recurrence following radical prostatectomy with an early imaging acquisition protocol with ¹⁸F-fluorocholine positron emission tomography/computed tomography.
    Simone G; Di Pierro GB; Papalia R; Sciuto R; Rea S; Ferriero M; Guaglianone S; Maini CL; Gallucci M
    World J Urol; 2015 Oct; 33(10):1511-8. PubMed ID: 25577130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy.
    Fuccio C; Castellucci P; Schiavina R; Guidalotti PL; Gavaruzzi G; Montini GC; Nanni C; Marzola MC; Rubello D; Fanti S
    Eur J Radiol; 2012 Aug; 81(8):e893-6. PubMed ID: 22621862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
    Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
    Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.
    Lépinoy A; Cochet A; Cueff A; Cormier L; Martin E; Maingon P; Bosset JF; Brunotte F; Créhange G
    Radiother Oncol; 2014 Apr; 111(1):120-5. PubMed ID: 24780635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.
    Langsteger W; Balogova S; Huchet V; Beheshti M; Paycha F; Egrot C; Janetschek G; Loidl W; Nataf V; Kerrou K; Pascal O; Cussenot O; Talbot JN
    Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):448-57. PubMed ID: 21738117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective comparative study of
    Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
    Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ¹⁸F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging.
    McCarthy M; Siew T; Campbell A; Lenzo N; Spry N; Vivian J; Morandeau L
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):14-22. PubMed ID: 20862471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.